MYC-Nonamplified Secondary Lymphatic-Type Angiosarcoma With Prominent Lymphocytic Infiltrate Following Radiation Therapy for Myxoid Liposarcoma

Am J Dermatopathol. 2022 Dec 1;44(12):955-957. doi: 10.1097/DAD.0000000000002306. Epub 2022 Sep 27.

Abstract

Cutaneous angiosarcomas (AS) are uncommon and morphologically heterogeneous. Recently, a distinctive lymphatic-type AS with prominent lymphocytic infiltrate has been observed. Although conventional AS typically bear poor prognosis, lymphatic-type AS with prominent lymphocytic infiltrate and pseudolymphomatous AS show prolonged survival with rare extracutaneous spread. We describe a unique case of AS in a 55-year-old woman who received surgical resection and radiation therapy for her prior myxoid liposarcoma. She developed a suspected recurrence 15 years later. Microscopically, the lesion showed an infiltration of the reticular dermis by irregular interanastamosing vascular spaces lined by atypical endothelial cells with nuclear "hobnailing" and hyperchromasia. A prominent intratumoral and peritumoral lymphocytic infiltrate obscuring the tumor cells was also present. The tumor cells were diffusely positive for endothelial cell markers, including D2-40. Notably, there was no evidence of MYC gene amplification by FISH. Additional NGS-based molecular analysis demonstrated no significant genetic mutations. The patient is alive with a history of two local recurrences, but no evidence of metastasis. We present this case to raise awareness of MYC-nonamplified secondary lymphatic-type AS with prominent lymphocytic infiltrate (pseudolymphomatous AS) and to discuss its differential diagnosis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Endothelial Cells / pathology
  • Female
  • Hemangiosarcoma* / diagnosis
  • Hemangiosarcoma* / genetics
  • Hemangiosarcoma* / radiotherapy
  • Humans
  • Liposarcoma, Myxoid* / genetics
  • Liposarcoma, Myxoid* / radiotherapy
  • Lymphatic Vessels* / pathology
  • Pseudolymphoma*
  • Skin Neoplasms* / pathology